Compare INTA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTA | PGEN |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2021 | 2013 |
| Metric | INTA | PGEN |
|---|---|---|
| Price | $43.43 | $4.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $43.00 | $13.67 |
| AVG Volume (30 Days) | 762.6K | ★ 6.8M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | ★ $577,805,000.00 | $230,981,000.00 |
| Revenue This Year | $14.28 | $2,380.31 |
| Revenue Next Year | $14.95 | $84.01 |
| P/E Ratio | ★ N/A | $34.63 |
| Revenue Growth | ★ 14.62 | N/A |
| 52 Week Low | $19.01 | $3.04 |
| 52 Week High | $48.19 | $8.98 |
| Indicator | INTA | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 31.74 |
| Support Level | $24.91 | $3.89 |
| Resistance Level | $44.33 | $4.41 |
| Average True Range (ATR) | 2.03 | 0.36 |
| MACD | -0.42 | -0.01 |
| Stochastic Oscillator | 40.88 | 16.78 |
Intapp Inc is a provider of AI-powered solutions for professional firms in regulated industries. Its vertically tailored solutions are purpose-built for the specialized workflows, complex relationship networks, and professional compliance requirements of accounting, consulting, investment banking, legal, private capital, and real assets firms. By applying Firm AI to core processes and data, Intapp helps partners, dealmakers, and advisors drive firm growth, manage compliance, and improve profitability. Its products include AI & Data Platform, Intapp Celeste and Firm AI, and Intapp Integration Service. The Company operates in accounting, consulting, corporate, investment banking and advisory, and other industries. The Company operates in the UK and the US, with maximum revenue from the US.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.